• Facebook-Icon
  • Twitter-Icon
  • linked-in-icon

Launch of Brilinta® (Ticagrelor) Tablets

Released: 05/14/2025  

Generic Brilinta Launch

Generic Brilinta® (Ticagrelor) has been approved by the FDA.

Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS), or a history of MI.

Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS, and the risk of a first MI or stroke in patients with coronary artery disease (CAD), acute ischemic stroke (NIH Stroke Scale score ≤ 5), or high-risk transient ischemic attack (TIA).

Ticagrelor 60 mg and 90 mg tablets will be manufactured by multiple manufacturers, including Alembic, Novadoz, Ascend, Teva, and Hisun Pharmaceuticals.

The post Launch of Brilinta® (Ticagrelor) Tablets appeared first on Carlisle Medical.

Filter Articles